Business Context and Reporting Period
This Form 8-K reports on the results of the 2020 Annual Meeting of Stockholders for Protagonist Therapeutics, Inc., held on May 28, 2020. The company is an emerging growth company incorporated in Delaware, with its common stock (PTGX) trading on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results rather than financial performance.
Material Changes and Voting Results
Two proposals were submitted to stockholders, both of which were approved:
- Proposal 1 (Election of Directors): Two Class I directors were elected to serve until the 2023 Annual Meeting.
- Dinesh V. Patel, Ph.D.: 16,515,423 votes For; 1,916,749 votes Withheld; 3,542,396 Broker Non-Votes.
- Sarah Noonberg, M.D., Ph.D.: 16,397,931 votes For; 2,034,241 votes Withheld; 3,542,396 Broker Non-Votes.
- Proposal 2 (Ratification of Auditors): The selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2020, was ratified.
- Votes For: 21,966,944
- Votes Against: 3,185
- Abstain: 4,439
- Broker Non-Votes: None
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document serves solely to disclose the outcome of the stockholder vote.
Key Facts for Investor Verification
- Verify the definitive proxy statement filed on April 16, 2020, for detailed biographies of the elected directors and the rationale for the auditor selection.
- Confirm the total number of shares outstanding to calculate the percentage of votes cast for each proposal.
- Note the significant number of broker non-votes (3,542,396) on the director election, indicating shares held in street name where brokers lacked discretionary voting power.